Latest update - COMPULSE study
NeoDynamics carries out a couple of studies in Europe to support their promising Neonavia product and upcoming launch in US.
COMPULSE - Randomized controlled multicentre study.
British study on comparison between NeoNavia (NeoDynamics) and conventional 14G CNB for tissue sampling in axillary lymph nodes (COMPULSE).
Watch the video:
NeoDynamics AB (publ) a Swedish medical technology company dedicated to advancing the diagnostics and treatment of cancer. The company has created an innovative biopsy system called NeoNavia®. This biopsy system builds on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The innovative pulse biopsy system is designed to offer clinicians and patients reliable tissue sampling with high tissue yield for correct diagnosis and individualised treatment. NeoNavia has been launched on the Swedish, German, and British market.
NeoDynamics is listed on Nasdaq First North Growth Market in Stockholm.
Login required
This content is only available for logged in users
